Pharma

Pharmalot By Elizabeth Cooney

Pharmalittle: ICER medical experts find no benefit for Aduhelm; FDA panel votes down Fibrogen’s anemia drug

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits

Pharmalot By Ed Silverman

U.K. issues record fine to drug makers for price gouging and collusion schemes

Pharmalot By Ed Silverman

Pharmalittle: FDA head admits possible missteps in Alzheimer’s drug approval; two major health systems won’t administer Biogen drug

Pharmalot By Ed Silverman

FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug

Pharmalot By Ed Silverman

Pharmalittle: Half-dozen big insurers won’t cover new Alzheimer’s drug; Medicaid could spend up to $2.2 billion on the Biogen drug

Pharmalot By Ed Silverman

Insulin makers and pharmacy benefit managers must face racketeering claims in a lawsuit

STAT Summit By Elizabeth Cooney

‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Pharmalot By Ed Silverman

Biogen’s new Alzheimer’s drug could cost Medicaid up to $2.2 billion a year

Pharmalot By Ed Silverman

Pharmalittle: Medicare starts coverage review for Biogen Alzheimer’s drug; U.S. needs more data before deciding on Covid booster shot

Pharmalot By Ed Silverman

Biden’s executive order would pause a Trump rule forbidding march-in rights to lower drug costs

Pharmalot By Ed Silverman

Dozens of generic makers and pharmacies won’t face lawsuits over Zantac and cancer risks

Pharmalot By Ed Silverman

Pharmalittle: U.S. officials and Pfizer to meet over Covid-19 booster shots; FDA full approval for vaccines may not be a game changer

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Damian Garde

Pharmalittle: Even FDA officials balked at the broad Aduhelm label; CDC and FDA are dubious about Covid booster shots

Pharmalot By Ed Silverman

FDA extends shelf life for glaucoma drug discontinued by Pfizer, but patients remain concerned

Health By Lauran Neergaard — Associated Press

Pfizer to seek FDA authorization for third, booster dose of its Covid-19 vaccine

Pharmalot By Ed Silverman

House Democrats say pharma stock buybacks and dividends exceed R&D spending

Pharmalot By Ed Silverman

Former Genentech scientist convicted of stealing trade secrets given to former JHL Biotech execs

Pharmalot By Ed Silverman

Purdue reaches deal with 15 states in a significant step toward bankruptcy plan approval

Pharmalot By Ed Silverman

Pharmalittle: In rare move, FDA revises label for Biogen Alzheimer’s drug; former compounding exec gets added jail time

Pharmalot By Ed Silverman

Pharmalittle: Another lawmaker calls for probe of FDA approval of Alzheimer’s drug; Roche urged to lower price of Covid-19 therapy

Pharmalot By Ed Silverman

Doctors Without Borders urges Roche to cut price of drug now recommended for Covid-19

Pharmalot By Ed Silverman

Pharmalittle: Purdue wants to shower employees with $34.7 million in bonuses; Emergent faces shareholder suits

Pharmalot By Ed Silverman

Regulators in many European countries fail to ensure clinical trial data are available

Pharmalot By Ed Silverman

Purdue wants to shower employees with nearly $35 million in different kinds of bonuses

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: Glaxo rejects hedge fund’s demands; FTC approves resolutions to probe pharma repeat offenders